Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Nautilus Biotechnolgy ( (NAUT) ) has shared an announcement.
On November 3, 2025, Nautilus Biotechnology, Inc. announced that it has regained compliance with Nasdaq’s Listing Rule 5550(a)(2), ensuring its continued listing on The Nasdaq Capital Market. This follows a previous notice in May 2025, when the company failed to meet the minimum bid price requirement. After transferring to The Nasdaq Capital Market in October 2025, Nautilus Biotechnology successfully met the compliance requirements, closing the matter.
The most recent analyst rating on (NAUT) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Nautilus Biotechnolgy stock, see the NAUT Stock Forecast page.
Spark’s Take on NAUT Stock
According to Spark, TipRanks’ AI Analyst, NAUT is a Neutral.
Nautilus Biotechnology’s score reflects its early-stage status with high operational losses and zero revenue, typical for biotech firms focused on R&D. While its strong cash reserves and low leverage offer some stability, persistent losses and slow pharma partnerships pose significant risks. Technical indicators suggest a bearish trend, but the earnings call highlighted positive advancements in proteomics and cost efficiencies, offering a cautiously optimistic outlook.
To see Spark’s full report on NAUT stock, click here.
More about Nautilus Biotechnolgy
Average Trading Volume: 455,703
Technical Sentiment Signal: Hold
Current Market Cap: $233.7M
For a thorough assessment of NAUT stock, go to TipRanks’ Stock Analysis page.